Daniel Westaby

544 total citations
9 papers, 143 citations indexed

About

Daniel Westaby is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniel Westaby has authored 9 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Daniel Westaby's work include Prostate Cancer Treatment and Research (7 papers), Bone health and treatments (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Daniel Westaby is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Bone health and treatments (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Daniel Westaby collaborates with scholars based in United Kingdom, United States and Switzerland. Daniel Westaby's co-authors include Johann S. de Bono, Adam Sharp, Juan M. Jiménez‐Vacas, Maria D. Fenor de la Maza, Alec Paschalis, Jon Welti, Andreas Varkaris, Steven P. Balk, Andrew W. Hahn and Mark T. Fleming and has published in prestigious journals such as Journal of Clinical Oncology, The Annual Review of Pharmacology and Toxicology and European Radiology.

In The Last Decade

Daniel Westaby

8 papers receiving 142 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Westaby United Kingdom	5	84	57	37	31	14	9	143
Ariel M. Ley United States	7	44 0.5×	72 1.3×	34 0.9×	40 1.3×	14 1.0×	9	183
Narayanan Srihari United Kingdom	5	69 0.8×	36 0.6×	48 1.3×	47 1.5×	9 0.6×	8	128
Tyler Kolisnik Canada	5	100 1.2×	61 1.1×	59 1.6×	30 1.0×	9 0.6×	10	173
Maria D. Fenor de la Maza United Kingdom	7	85 1.0×	53 0.9×	32 0.9×	56 1.8×	13 0.9×	17	152
Jon Welti United Kingdom	2	74 0.9×	34 0.6×	28 0.8×	26 0.8×	11 0.8×	3	101
Joel Roger Gingerich Canada	6	67 0.8×	54 0.9×	35 0.9×	44 1.4×	8 0.6×	17	143
G. Yu. Chemeris Russia	8	45 0.5×	93 1.6×	33 0.9×	41 1.3×	17 1.2×	17	143
Rebecca Wu Canada	4	31 0.4×	30 0.5×	25 0.7×	17 0.5×	11 0.8×	8	105
Fanshuang Zhang China	8	59 0.7×	70 1.2×	43 1.2×	47 1.5×	8 0.6×	18	171

Countries citing papers authored by Daniel Westaby

Since Specialization

Citations

This map shows the geographic impact of Daniel Westaby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Westaby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Westaby more than expected).

Fields of papers citing papers by Daniel Westaby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Westaby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Westaby. The network helps show where Daniel Westaby may publish in the future.

Co-authorship network of co-authors of Daniel Westaby

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Westaby. A scholar is included among the top collaborators of Daniel Westaby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Westaby. Daniel Westaby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Rescigno, Pasquale, Maria D. Fenor de la Maza, Stephanie Burnett, et al.. (2024). Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).. Journal of Clinical Oncology. 42(4_suppl). 138–138. 1 indexed citations

Neeb, Antje, Ines Figueiredo, Bora Gürel, et al.. (2023). Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer. Laboratory Investigation. 103(11). 100245–100245.

Carreira, Suzanne, Susana Miranda, Ines Figueiredo, et al.. (2023). Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. European Urology Open Science. 52. 72–78. 5 indexed citations

Figueiredo, Ines, Daniel Westaby, Dow‐Mu Koh, et al.. (2023). Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer. Cancer Imaging. 23(1). 121–121. 3 indexed citations

Fotiadis, Nicos, Ines Figueiredo, Matthew Blackledge, et al.. (2022). Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients. European Radiology. 32(10). 6820–6829. 4 indexed citations

Westaby, Daniel, Rahul Ravilla, Maria D. Fenor de la Maza, et al.. (2021). Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book. 41(41). e190–e202. 15 indexed citations

Westaby, Daniel, Juan M. Jiménez‐Vacas, Andreas Varkaris, et al.. (2021). Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers. 14(1). 51–51. 29 indexed citations

Westaby, Daniel, Maria D. Fenor de la Maza, Alec Paschalis, et al.. (2021). A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. The Annual Review of Pharmacology and Toxicology. 62(1). 131–153. 78 indexed citations

Westaby, Daniel, Olívia Wu, W. Colin Duncan, et al.. (2012). Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery?. BMC Pregnancy and Childbirth. 12(1). 98–98. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact